Literature DB >> 31493497

Carrier-free nanodrug: A novel strategy of cancer diagnosis and synergistic therapy.

Ming-Yue Yang1, Rui-Rui Zhao1, Yi-Fan Fang1, Jia-Li Jiang1, Xiao-Tian Yuan1, Jing-Wei Shao2.   

Abstract

Nanoformulations with advantages in drug delivery, safety and pharmacodynamics have been booming as a promising strategy for cancer therapy. However, the traditional nanocarrier still suffers from the low drug loading capacity, potential systematic toxicity, unclear metabolism, and other uncertainties. To overcome these issues, carrier-free nanodrugs with desirable bioactivity were developed rapidly and drawn considerable attention. Meanwhile, the multifunctional self-delivery nanoarcheticture fabricated by a simple and "green" method, has significant advantages in synergistic cancer therapy and inhibition of multidrug resistant (MDR). Till now, carrier-free nanoparticles for tumor theranostics, phototherapy, chemotherapy, diagnose and synergistic therapy, have made outstanding progress. In this review, we make an integrated and exhaustive overview of lately reports on carrier-free nanodrug delivery systems formed by several active agents. We summarize the self-assembly and modified strategies, with emphasis on application superiority of carrier-free nanocrystal, and give new insight into the establishment of ideal nanosystems for cancer treatment.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carrier-free; Nanodrug; Self-assembly; Synergistic cancer therapy

Mesh:

Substances:

Year:  2019        PMID: 31493497     DOI: 10.1016/j.ijpharm.2019.118663

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  Self-assembling, pH-responsive nanoflowers for inhibiting PAD4 and neutrophil extracellular trap formation and improving the tumor immune microenvironment.

Authors:  Di Zhu; Yu Lu; Lin Gui; Wenjing Wang; Xi Hu; Su Chen; Yanming Wang; Yuji Wang
Journal:  Acta Pharm Sin B       Date:  2021-11-12       Impact factor: 14.903

2.  Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy.

Authors:  Yue Jiang; Chunzhi Huang; Yuxia Luan
Journal:  Int J Nanomedicine       Date:  2020-06-22

Review 3.  Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy.

Authors:  Mona Sadat Mirtaleb; Amir Hossein Mirtaleb; Hassan Nosrati; Jalal Heshmatnia; Reza Falak; Reza Zolfaghari Emameh
Journal:  Biomed Pharmacother       Date:  2021-03-16       Impact factor: 7.419

Review 4.  Recent Progress of Novel Nanotechnology Challenging the Multidrug Resistance of Cancer.

Authors:  Chengyuan Zhang; Xuemei Zhou; Hanyi Zhang; Xuanliang Han; Baijun Li; Ran Yang; Xing Zhou
Journal:  Front Pharmacol       Date:  2022-02-14       Impact factor: 5.810

5.  Mitochondria-acting carrier-free nanoplatform self-assembled by α-tocopheryl succinate carrying cisplatin for combinational tumor therapy.

Authors:  Heng Mei; Jing Li; Shengsheng Cai; Xuequan Zhang; Wenqiang Shi; Hai Zhu; Jun Cao; Bin He
Journal:  Regen Biomater       Date:  2021-06-30

Review 6.  Evolution from small molecule to nano-drug delivery systems: An emerging approach for cancer therapy of ursolic acid.

Authors:  Jingwei Shao; Yifan Fang; Ruirui Zhao; Fangmin Chen; Mingyue Yang; Jiali Jiang; Zixuan Chen; Xiaotian Yuan; Lee Jia
Journal:  Asian J Pharm Sci       Date:  2020-03-21       Impact factor: 6.598

Review 7.  Research Progress of Carrier-Free Antitumor Nanoparticles Based on Phytochemicals.

Authors:  Siliang Jiang; Yu Fu; Xinyang Zhang; Tong Yu; Bowen Lu; Juan Du
Journal:  Front Bioeng Biotechnol       Date:  2021-12-08

Review 8.  Self-Assembled Porphyrinoids: One-Component Nanostructured Photomedicines.

Authors:  Irene Paramio; Tomás Torres; Gema de la Torre
Journal:  ChemMedChem       Date:  2021-05-19       Impact factor: 3.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.